VIDEO: Inebilizumab reduces plasma cell signature, B-cell intrusion in NMOSD attacks
Click Here to Manage Email Alerts
Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica spectrum disorder, Bruce A. Cree, MD, PhD, MAS, said in this Healio video.
Cree and colleagues sought to evaluate the relationship between peripheral blood B-cell subsets andaquaporin-4 (AQP4) immunoglobulin G (IgG) titers and neuromyelitis optica spectrum disorder (NMOSD) attacks for individuals within the N-Momentum trial.
For individuals who had a clinical attack, Cree noted, there was an increase from baseline by a little over twofold, indicating that plasma cell activity was increased, along with a twofold increase in B cells at the time of an attack.
Researchers found that treatment with inebilizumab led to reduction in both plasma cell signatures and B cells at the time of attack, while also resulting in a lack of increase of AQP4 IgG titers compared with those in the placebo group.
“We still don’t know why NMOSD patients experience attacks, what triggers attacks, what the actual mechanisms are at work during the course of an attack,” Cree stated. “So this type of work creates important insights.”